Tech Company Financing Transactions
Dash Bio Funding Round
Oak HC/FT, Freestyle Capital and Swift Ventures joined a $30 million Series A funding round for Dash Bio. The round was announced by the company on 8/3/2026.
Transaction Overview
Company Name
Announced On
8/3/2026
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to continue to scale its commercial operations, expand its assay menu and laboratory capacity, expand into new categories, and continue development of its proprietary software platform.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
56 Broad St. 14011
Boston, MA 02109
USA
Boston, MA 02109
USA
Phone
Undisclosed
Website
Email Address
Overview
While drug discovery is advancing exponentially, drug development is utterly outdated. Until now. Biotech has never been more innovative. mRNA technology has changed how we make vaccines, CRISPR is rewriting the genome, and there are hundreds of AI drug discovery startups promising to fundamentally transform how we discover new potential medicines.Yet despite this immense innovation, drug development remains stuck in the past.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dave Johnson
Chief Operating Officer
Ander Tallett
Chief Scientific Officer
Ely Porter
Browse more venture capital transactions:
Prev: 8/3/2026: RevealDX venture capital transaction
Next: 8/3/2026: Zenity venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs